-Reuters
Goldman Sachs Downgrades HUTCHMED (China) to Neutral, Announces $46 Price Target
Goldman Sachs analyst Paul Choi downgrades HUTCHMED (China) (NASDAQ:HCM) from Buy to Neutral and announces $46 price target.
Related Posts
Citigroup Downgrades EQT to Neutral, Lowers Price Target to $40
Citigroup analyst Paul Diamond downgrades EQT (NYSE:EQT) from Buy to Neutral and lowers the price target from $60 to $40.
Norfolk Southern Reopens Kentucky Intermodal Terminal
Norfolk Southern has reopened an intermodal terminal serving Louisville, Kentucky, in light of "strong growth" in the intermodal market there.
Low-Volume Issue, XTL Biopharma Shares Spike To Session High Following Tweet From Unverified Twitter Account XTL Biopharma ‘Excited to share XTL Bio has accepted a shareholder’s tender off to take the company private at USD $8.75/share ADRs’
https://twitter.com/XTLBiopharma/status/1453385300949012495